Solostar Injection Pen Approved for Diabetes
Prefilled with Apidra, a rapid-acting insulin
THURSDAY, Feb. 26, 2009 (HealthDay News) -- Sanofi-Aventis's Apidra (insulin glulisine) Solostar injection pen has been approved to treat diabetes, the company said Thursday in a news release.
The disposable pen with rapid-acting insulin was approved for adults with type 2 diabetes and for children four years and older with type 1 diabetes.
The device requires lower injection force than competing products, the drug maker said.
The FDA has additional information about Apidra, a drug first approved in 2004.